Arab Finance: Minapharm Pharmaceuticals' board of directors has discussed the terms and conditions of a loan worth €13.25 million from the European Bank for Reconstruction and Development (EBRD), according to a disclosure to the Egyptian Exchange (EGX).

The company aims to use the potential loan to refinance part of its short- and medium-term borrowings, as well as to fund capital expenditures and product development at its new production facility.

The financing will also partially support the development of a new vocational training academy.

Established in 1958, the company produces licensed and generic pharmaceuticals, vaccines, veterinary products, drug delivery systems, cosmetics, and skin care supplies. The company's expertise covers a broad spectrum of medicines, ranging from small molecules to extremely complex bioengineered proteins.

EBRD extends $20M green finance facility to ALEXBANK Updated 12/21/2025 8:05:00 AM

Madbouly reaffirms government’s focus on cutting public, external debt Updated 12/17/2025 8:04:00 AM

CBE, EBRD launch MasterTalks for banking sector development Updated 12/16/2025 10:50:00 AM

EBRD approves €200M financing to back Egypt’s transition to green economy Updated 12/16/2025 8:00:00 AM

Egypt, EBRD sign 6 agreements on investment, energy Updated 12/10/2025 10:47:00 AM